presentation2.2-session 2- schmitt .ppt neurodermatitis) all others outcome clinical signs •...
TRANSCRIPT
![Page 1: Presentation2.2-Session 2- Schmitt .ppt neurodermatitis) all others Outcome clinical signs • exclusively symptoms, quality of ... Presentation2.2-Session 2- Schmitt .ppt [Compatibility](https://reader034.vdocuments.mx/reader034/viewer/2022051801/5ade29ff7f8b9ae1408e02fb/html5/thumbnails/1.jpg)
Jochen Schmitt, Stefanie Deckert, Sinead Langan, AkeSvensson, Laura von Kobyletzki, Kim Thomas, Phyllis Spuls
HOME IIIHOME IIIMeasurement properties of outcome
measurements for atopic dermatitis signs
San Diego, April 6-7, 2013
![Page 2: Presentation2.2-Session 2- Schmitt .ppt neurodermatitis) all others Outcome clinical signs • exclusively symptoms, quality of ... Presentation2.2-Session 2- Schmitt .ppt [Compatibility](https://reader034.vdocuments.mx/reader034/viewer/2022051801/5ade29ff7f8b9ae1408e02fb/html5/thumbnails/2.jpg)
Background
![Page 3: Presentation2.2-Session 2- Schmitt .ppt neurodermatitis) all others Outcome clinical signs • exclusively symptoms, quality of ... Presentation2.2-Session 2- Schmitt .ppt [Compatibility](https://reader034.vdocuments.mx/reader034/viewer/2022051801/5ade29ff7f8b9ae1408e02fb/html5/thumbnails/3.jpg)
Objective: to identify and critically appraise all named outcome measurementsspecifically designed for AD to measure disease severity
ADAM Atopic Dermatitis Assessment Measure
ADASI Atopic Dermatitis Area and Severity Index
ADSI Atopic Dermatitis Severity Index
BCSS Basic Clinical Scoring SystemBCSS Basic Clinical Scoring System
EASI Eczema Area and Severity Index
FSSS Four Step Severity Score
IGADA Investigators´ Global Atopic Dermatitis Assessment
Leicester Leicester index
NESS Nottingham Eczema Severity Score
OSAAD Objective Severity Assessment of Atopic Dermatitis
POEM Patient-Oriented Eczema Measure
RL Score Rajka and Langeland Score
SA-EASI self-administered Eczema Area and Severity Index
SASSAD Six Area, Six Sign Atopic Dermatitis severity score
SCORAD Severity Scoring of Atopic Dermatitis index
SIS Skin Intensity Score
SSS Simple Scoring System
TBSA 6-area Total Body Severity Assessment
TIS Three Item Severity Score
W-AZS (Polish acronym for atopic dermatitis severity score)
![Page 4: Presentation2.2-Session 2- Schmitt .ppt neurodermatitis) all others Outcome clinical signs • exclusively symptoms, quality of ... Presentation2.2-Session 2- Schmitt .ppt [Compatibility](https://reader034.vdocuments.mx/reader034/viewer/2022051801/5ade29ff7f8b9ae1408e02fb/html5/thumbnails/4.jpg)
![Page 5: Presentation2.2-Session 2- Schmitt .ppt neurodermatitis) all others Outcome clinical signs • exclusively symptoms, quality of ... Presentation2.2-Session 2- Schmitt .ppt [Compatibility](https://reader034.vdocuments.mx/reader034/viewer/2022051801/5ade29ff7f8b9ae1408e02fb/html5/thumbnails/5.jpg)
Criteria for recommendations
A total relative score ranging from 0% to 100%was calculated for each outcome measurement
Score Recommendation Reason
> 90% highly recommended measurement is valid & reliable
70-90% recommended measurement meets most validitycriteria
50-69% acceptable but notrecommended
validity criteria only partly met
30-49% not recommended significant validity criteria are notmet or have not been evaluated
< 30% not acceptable measurement is invalid or has notbeen validated
![Page 6: Presentation2.2-Session 2- Schmitt .ppt neurodermatitis) all others Outcome clinical signs • exclusively symptoms, quality of ... Presentation2.2-Session 2- Schmitt .ppt [Compatibility](https://reader034.vdocuments.mx/reader034/viewer/2022051801/5ade29ff7f8b9ae1408e02fb/html5/thumbnails/6.jpg)
Recommendations
Recommendation Outcome measurement
highly recommended
recommended EASI, SCORAD, POEM
acceptable but notrecommended
IGADA, NESS, SA-EASI, SASSAD, TIS
not recommended ADAM, ADASI, BCSS, Leicester Index,RL Score, SSS
not acceptable ADSI, FSSS, OSAAD, SIS, TBSA, WAZ-S
JACI 2007; 120:1389-98
![Page 7: Presentation2.2-Session 2- Schmitt .ppt neurodermatitis) all others Outcome clinical signs • exclusively symptoms, quality of ... Presentation2.2-Session 2- Schmitt .ppt [Compatibility](https://reader034.vdocuments.mx/reader034/viewer/2022051801/5ade29ff7f8b9ae1408e02fb/html5/thumbnails/7.jpg)
Objectives of systematic review
1. To systematically assess measurement properties of outcome measurements foratopic dermatitis signs
2. To identify outcome measures for atopic dermatitis signs
– that meet the predefined criteria (OMERACT Filter) to be recommended for themeasurement of signs in future atopic dermatitis trials
– that have the potential to be recommended in the future depending on the– that have the potential to be recommended in the future depending on theresults of further validation studies
– that do not meet the predefined criteria to be recommended and thereforeshould not be used any more.
3. To provide the evidence base
– for an international consensus process to further standardize the assessment ofatopic dermatitis signs in clinical trials.
– for an international consensus process to prioritize further research concerningatopic dermatitis signs outcome assessment.
![Page 8: Presentation2.2-Session 2- Schmitt .ppt neurodermatitis) all others Outcome clinical signs • exclusively symptoms, quality of ... Presentation2.2-Session 2- Schmitt .ppt [Compatibility](https://reader034.vdocuments.mx/reader034/viewer/2022051801/5ade29ff7f8b9ae1408e02fb/html5/thumbnails/8.jpg)
Methods
![Page 9: Presentation2.2-Session 2- Schmitt .ppt neurodermatitis) all others Outcome clinical signs • exclusively symptoms, quality of ... Presentation2.2-Session 2- Schmitt .ppt [Compatibility](https://reader034.vdocuments.mx/reader034/viewer/2022051801/5ade29ff7f8b9ae1408e02fb/html5/thumbnails/9.jpg)
A priori study protocol
![Page 10: Presentation2.2-Session 2- Schmitt .ppt neurodermatitis) all others Outcome clinical signs • exclusively symptoms, quality of ... Presentation2.2-Session 2- Schmitt .ppt [Compatibility](https://reader034.vdocuments.mx/reader034/viewer/2022051801/5ade29ff7f8b9ae1408e02fb/html5/thumbnails/10.jpg)
Research question
…divided by PICOS-criteria
Which(P) atopic dermatitis
(I and C) not applicable
(O) outcome measurements exist to assessdisease severity and were investigatedregarding to
(S) measurement properties?
![Page 11: Presentation2.2-Session 2- Schmitt .ppt neurodermatitis) all others Outcome clinical signs • exclusively symptoms, quality of ... Presentation2.2-Session 2- Schmitt .ppt [Compatibility](https://reader034.vdocuments.mx/reader034/viewer/2022051801/5ade29ff7f8b9ae1408e02fb/html5/thumbnails/11.jpg)
Inclusion and exclusion criteria for studyselection
inclusion exclusion
Population atopic eczema (syn: eczema, atopic,dermatitis, neurodermatitis)
all others
Outcome clinical signs • exclusively symptoms, quality oflife or other domains investigatedlife or other domains investigated
• biomarker or skin physiologymeasures as comparators
StudyDesign
• validation studies or inauguration
• papers with at least one of thefollowing measurement properties:
content validity, construct validity,internal consistency, reliability,senisitivity to change, floor or ceilingeffects, interpretability, acceptability
• articles that report an eligible scalewithout any explicit validation
• linguistic validation
• studies which assess discriminantvalidity only
![Page 12: Presentation2.2-Session 2- Schmitt .ppt neurodermatitis) all others Outcome clinical signs • exclusively symptoms, quality of ... Presentation2.2-Session 2- Schmitt .ppt [Compatibility](https://reader034.vdocuments.mx/reader034/viewer/2022051801/5ade29ff7f8b9ae1408e02fb/html5/thumbnails/12.jpg)
Systematic literature search
• Systematic electronic search
Medline via PubMed and EMBASE via Ovid (up to Oct1st 2012)
("dermatitis, atopic"[MeSH] OR atopic dermatitis[tiab] OR atopic eczema[tiab] OReczema[MeSH] OR eczema[tiab] OR "neurodermatitis"[MeSH] OR Neurodermatitis[tiab])
ANDAND
((“Severity of Illness Index”[mh:noexp] OR “Severity of Illness Index”[tiab] OR ((severity[tiab]OR severe[tiab]) AND (scor*[tiab] OR measure*[tiab] OR item[tiab] OR index[tiab] ORinstrument[tiab] OR questionnaire[tiab] or scal*[tiab] or tool*[tiab] or assessment[tiab])))….
AND
(instrumentation[sh] OR methods[sh] OR Validation Studies[pt] OR Comparative Study[pt]OR “psychometrics”[MeSH] OR psychometr*[tiab] OR clinimetr*[tw] OR clinometr*[tw] OR“outcome assessment (health care)”[MeSH] OR outcome assessment[tiab] OR outcomemeasure*[tw]……
NOT
(“animals”[MeSH Terms] NOT “humans”[MeSH Terms])
![Page 13: Presentation2.2-Session 2- Schmitt .ppt neurodermatitis) all others Outcome clinical signs • exclusively symptoms, quality of ... Presentation2.2-Session 2- Schmitt .ppt [Compatibility](https://reader034.vdocuments.mx/reader034/viewer/2022051801/5ade29ff7f8b9ae1408e02fb/html5/thumbnails/13.jpg)
Systematic literature search
• Systematic electronic search
Medline via PubMed and EMBASE via Ovid (up to Oct1st 2012)
• Hand search
search of reference lists of studies included and key search of reference lists of studies included and keyarticles on this topic
![Page 14: Presentation2.2-Session 2- Schmitt .ppt neurodermatitis) all others Outcome clinical signs • exclusively symptoms, quality of ... Presentation2.2-Session 2- Schmitt .ppt [Compatibility](https://reader034.vdocuments.mx/reader034/viewer/2022051801/5ade29ff7f8b9ae1408e02fb/html5/thumbnails/14.jpg)
Flow Chart
![Page 15: Presentation2.2-Session 2- Schmitt .ppt neurodermatitis) all others Outcome clinical signs • exclusively symptoms, quality of ... Presentation2.2-Session 2- Schmitt .ppt [Compatibility](https://reader034.vdocuments.mx/reader034/viewer/2022051801/5ade29ff7f8b9ae1408e02fb/html5/thumbnails/15.jpg)
Data extraction and quality assessment
• Data extraction and assessment for each “substudy”
• independent quality assessment
methodological quality of included studies based
on COSMIN checklist rating: a 4-point scaleon COSMIN checklist rating: a 4-point scale
“worse score counts”
rating of scale quality (see handout)
![Page 16: Presentation2.2-Session 2- Schmitt .ppt neurodermatitis) all others Outcome clinical signs • exclusively symptoms, quality of ... Presentation2.2-Session 2- Schmitt .ppt [Compatibility](https://reader034.vdocuments.mx/reader034/viewer/2022051801/5ade29ff7f8b9ae1408e02fb/html5/thumbnails/16.jpg)
Four categories of recommendation
A) Outcome measure meets all requirements to be recommended
for use.
B)Outcome measure meets two or more quality items, butperformance in all other required quality items is unclear, sothat the outcome measure has the potential to be recommendedin the future depending on the results of further validationin the future depending on the results of further validationstudies.
C)Outcome measure has low quality in at least one requiredquality criteria (≥1 rating of “minus“) and therefore is not recommended to be used any more
D)Outcome measure has (almost) not been validated. Itsperformance in all or most relevant quality items is unclear, so that itis not recommended to be used until further validation studies clarify
its quality.
![Page 17: Presentation2.2-Session 2- Schmitt .ppt neurodermatitis) all others Outcome clinical signs • exclusively symptoms, quality of ... Presentation2.2-Session 2- Schmitt .ppt [Compatibility](https://reader034.vdocuments.mx/reader034/viewer/2022051801/5ade29ff7f8b9ae1408e02fb/html5/thumbnails/17.jpg)
Results
![Page 18: Presentation2.2-Session 2- Schmitt .ppt neurodermatitis) all others Outcome clinical signs • exclusively symptoms, quality of ... Presentation2.2-Session 2- Schmitt .ppt [Compatibility](https://reader034.vdocuments.mx/reader034/viewer/2022051801/5ade29ff7f8b9ae1408e02fb/html5/thumbnails/18.jpg)
Summary of studies
•15 instruments identified to assess AD clinical signs
•published between 1989 and 2012
• most studies were conducted in the USA, UK, and NL
• most studies were performed on SCORAD (n=21) andEASI (n=10)
• study population consisted of more than 1,500 patientsfor both SCORAD and EASI including infants, children,and adults
![Page 19: Presentation2.2-Session 2- Schmitt .ppt neurodermatitis) all others Outcome clinical signs • exclusively symptoms, quality of ... Presentation2.2-Session 2- Schmitt .ppt [Compatibility](https://reader034.vdocuments.mx/reader034/viewer/2022051801/5ade29ff7f8b9ae1408e02fb/html5/thumbnails/19.jpg)
No. of validation substudies per scale
Quality item (name)S
CO
RA
D
TIS
EA
SI
SA
SS
AD
PO
EM
BC
SS
AD
AM
AD
AS
I
AD
Q
OS
AA
D
SS
S
W-A
ZS
Un
nam
ed
sale
1
Un
nam
ed
sale
2
Content validity3 2 2 2 3 1 1 2 1 1 2 2 2 2
Content validity3 2 2 2 3 1 1 2 1 1 2 2 2 2
Construct validity17 3 8 2 1 1 3 1
Internal consistency7 1 2 1 1
Intra-observer reliability1 1 1 1
Inter-observer reliability11 5 3 1 1 1 1 2 1 1
Sensitivity to change2 2 2 1
Floor or ceiling effects2 2 1 2 1
Interpretability2 1
Acceptability3 1 1 1 1 1 1 1
![Page 20: Presentation2.2-Session 2- Schmitt .ppt neurodermatitis) all others Outcome clinical signs • exclusively symptoms, quality of ... Presentation2.2-Session 2- Schmitt .ppt [Compatibility](https://reader034.vdocuments.mx/reader034/viewer/2022051801/5ade29ff7f8b9ae1408e02fb/html5/thumbnails/20.jpg)
Summary of scale domains and items(scale content)
![Page 21: Presentation2.2-Session 2- Schmitt .ppt neurodermatitis) all others Outcome clinical signs • exclusively symptoms, quality of ... Presentation2.2-Session 2- Schmitt .ppt [Compatibility](https://reader034.vdocuments.mx/reader034/viewer/2022051801/5ade29ff7f8b9ae1408e02fb/html5/thumbnails/21.jpg)
Two key studies on content validity …
![Page 22: Presentation2.2-Session 2- Schmitt .ppt neurodermatitis) all others Outcome clinical signs • exclusively symptoms, quality of ... Presentation2.2-Session 2- Schmitt .ppt [Compatibility](https://reader034.vdocuments.mx/reader034/viewer/2022051801/5ade29ff7f8b9ae1408e02fb/html5/thumbnails/22.jpg)
![Page 23: Presentation2.2-Session 2- Schmitt .ppt neurodermatitis) all others Outcome clinical signs • exclusively symptoms, quality of ... Presentation2.2-Session 2- Schmitt .ppt [Compatibility](https://reader034.vdocuments.mx/reader034/viewer/2022051801/5ade29ff7f8b9ae1408e02fb/html5/thumbnails/23.jpg)
Content validity: Expert and consumer surveya) Are the domains adequate to measure the severity of AD?
b) Are the items representative of the domain they areb) Are the items representative of the domain they aresupposed to measure?
Assessment of content validity of all domains and itemsincluded in the outcomes identified on 5-point Likert scale
• 12 consumers: 4 adult patients, 4 patients aged 8-14 years,4 caregivers of patients aged 1-7 years
• 6 clinical experts not involved in scale development
![Page 24: Presentation2.2-Session 2- Schmitt .ppt neurodermatitis) all others Outcome clinical signs • exclusively symptoms, quality of ... Presentation2.2-Session 2- Schmitt .ppt [Compatibility](https://reader034.vdocuments.mx/reader034/viewer/2022051801/5ade29ff7f8b9ae1408e02fb/html5/thumbnails/24.jpg)
Content validity of domains and items
![Page 25: Presentation2.2-Session 2- Schmitt .ppt neurodermatitis) all others Outcome clinical signs • exclusively symptoms, quality of ... Presentation2.2-Session 2- Schmitt .ppt [Compatibility](https://reader034.vdocuments.mx/reader034/viewer/2022051801/5ade29ff7f8b9ae1408e02fb/html5/thumbnails/25.jpg)
Summary of scale domains and items(scale content)
![Page 26: Presentation2.2-Session 2- Schmitt .ppt neurodermatitis) all others Outcome clinical signs • exclusively symptoms, quality of ... Presentation2.2-Session 2- Schmitt .ppt [Compatibility](https://reader034.vdocuments.mx/reader034/viewer/2022051801/5ade29ff7f8b9ae1408e02fb/html5/thumbnails/26.jpg)
Summary of psychometric properties ofmeasures for clinical signs of eczema
![Page 27: Presentation2.2-Session 2- Schmitt .ppt neurodermatitis) all others Outcome clinical signs • exclusively symptoms, quality of ... Presentation2.2-Session 2- Schmitt .ppt [Compatibility](https://reader034.vdocuments.mx/reader034/viewer/2022051801/5ade29ff7f8b9ae1408e02fb/html5/thumbnails/27.jpg)
Summary of psychometric properties ofmeasures for clinical signs of eczema
![Page 28: Presentation2.2-Session 2- Schmitt .ppt neurodermatitis) all others Outcome clinical signs • exclusively symptoms, quality of ... Presentation2.2-Session 2- Schmitt .ppt [Compatibility](https://reader034.vdocuments.mx/reader034/viewer/2022051801/5ade29ff7f8b9ae1408e02fb/html5/thumbnails/28.jpg)
Summary of psychometric properties ofmeasures for clinical signs of eczema
![Page 29: Presentation2.2-Session 2- Schmitt .ppt neurodermatitis) all others Outcome clinical signs • exclusively symptoms, quality of ... Presentation2.2-Session 2- Schmitt .ppt [Compatibility](https://reader034.vdocuments.mx/reader034/viewer/2022051801/5ade29ff7f8b9ae1408e02fb/html5/thumbnails/29.jpg)
Summary of psychometric properties ofmeasures for clinical signs of eczema
![Page 30: Presentation2.2-Session 2- Schmitt .ppt neurodermatitis) all others Outcome clinical signs • exclusively symptoms, quality of ... Presentation2.2-Session 2- Schmitt .ppt [Compatibility](https://reader034.vdocuments.mx/reader034/viewer/2022051801/5ade29ff7f8b9ae1408e02fb/html5/thumbnails/30.jpg)
Summary of psychometric properties ofmeasures for clinical signs of eczema
![Page 31: Presentation2.2-Session 2- Schmitt .ppt neurodermatitis) all others Outcome clinical signs • exclusively symptoms, quality of ... Presentation2.2-Session 2- Schmitt .ppt [Compatibility](https://reader034.vdocuments.mx/reader034/viewer/2022051801/5ade29ff7f8b9ae1408e02fb/html5/thumbnails/31.jpg)
Eczema area and severity index (EASI)
![Page 32: Presentation2.2-Session 2- Schmitt .ppt neurodermatitis) all others Outcome clinical signs • exclusively symptoms, quality of ... Presentation2.2-Session 2- Schmitt .ppt [Compatibility](https://reader034.vdocuments.mx/reader034/viewer/2022051801/5ade29ff7f8b9ae1408e02fb/html5/thumbnails/32.jpg)
Eczema area and severity index (EASI)
![Page 33: Presentation2.2-Session 2- Schmitt .ppt neurodermatitis) all others Outcome clinical signs • exclusively symptoms, quality of ... Presentation2.2-Session 2- Schmitt .ppt [Compatibility](https://reader034.vdocuments.mx/reader034/viewer/2022051801/5ade29ff7f8b9ae1408e02fb/html5/thumbnails/33.jpg)
Eczema area and severity index (EASI)
![Page 34: Presentation2.2-Session 2- Schmitt .ppt neurodermatitis) all others Outcome clinical signs • exclusively symptoms, quality of ... Presentation2.2-Session 2- Schmitt .ppt [Compatibility](https://reader034.vdocuments.mx/reader034/viewer/2022051801/5ade29ff7f8b9ae1408e02fb/html5/thumbnails/34.jpg)
Eczema area and severity index (EASI)
![Page 35: Presentation2.2-Session 2- Schmitt .ppt neurodermatitis) all others Outcome clinical signs • exclusively symptoms, quality of ... Presentation2.2-Session 2- Schmitt .ppt [Compatibility](https://reader034.vdocuments.mx/reader034/viewer/2022051801/5ade29ff7f8b9ae1408e02fb/html5/thumbnails/35.jpg)
Eczema area and severity index (EASI)
![Page 36: Presentation2.2-Session 2- Schmitt .ppt neurodermatitis) all others Outcome clinical signs • exclusively symptoms, quality of ... Presentation2.2-Session 2- Schmitt .ppt [Compatibility](https://reader034.vdocuments.mx/reader034/viewer/2022051801/5ade29ff7f8b9ae1408e02fb/html5/thumbnails/36.jpg)
Eczema area and severity index (EASI)
![Page 37: Presentation2.2-Session 2- Schmitt .ppt neurodermatitis) all others Outcome clinical signs • exclusively symptoms, quality of ... Presentation2.2-Session 2- Schmitt .ppt [Compatibility](https://reader034.vdocuments.mx/reader034/viewer/2022051801/5ade29ff7f8b9ae1408e02fb/html5/thumbnails/37.jpg)
Severity Scoring of Atopic Dermatitis Index(SCORAD)
![Page 38: Presentation2.2-Session 2- Schmitt .ppt neurodermatitis) all others Outcome clinical signs • exclusively symptoms, quality of ... Presentation2.2-Session 2- Schmitt .ppt [Compatibility](https://reader034.vdocuments.mx/reader034/viewer/2022051801/5ade29ff7f8b9ae1408e02fb/html5/thumbnails/38.jpg)
Severity Scoring of Atopic Dermatitis Index (SCORAD)
![Page 39: Presentation2.2-Session 2- Schmitt .ppt neurodermatitis) all others Outcome clinical signs • exclusively symptoms, quality of ... Presentation2.2-Session 2- Schmitt .ppt [Compatibility](https://reader034.vdocuments.mx/reader034/viewer/2022051801/5ade29ff7f8b9ae1408e02fb/html5/thumbnails/39.jpg)
Severity Scoring of Atopic Dermatitis Index (SCORAD)
![Page 40: Presentation2.2-Session 2- Schmitt .ppt neurodermatitis) all others Outcome clinical signs • exclusively symptoms, quality of ... Presentation2.2-Session 2- Schmitt .ppt [Compatibility](https://reader034.vdocuments.mx/reader034/viewer/2022051801/5ade29ff7f8b9ae1408e02fb/html5/thumbnails/40.jpg)
Severity Scoring of Atopic Dermatitis Index (SCORAD)
![Page 41: Presentation2.2-Session 2- Schmitt .ppt neurodermatitis) all others Outcome clinical signs • exclusively symptoms, quality of ... Presentation2.2-Session 2- Schmitt .ppt [Compatibility](https://reader034.vdocuments.mx/reader034/viewer/2022051801/5ade29ff7f8b9ae1408e02fb/html5/thumbnails/41.jpg)
Severity Scoring of Atopic Dermatitis Index (SCORAD)
![Page 42: Presentation2.2-Session 2- Schmitt .ppt neurodermatitis) all others Outcome clinical signs • exclusively symptoms, quality of ... Presentation2.2-Session 2- Schmitt .ppt [Compatibility](https://reader034.vdocuments.mx/reader034/viewer/2022051801/5ade29ff7f8b9ae1408e02fb/html5/thumbnails/42.jpg)
Severity Scoring of Atopic Dermatitis Index (SCORAD)
![Page 43: Presentation2.2-Session 2- Schmitt .ppt neurodermatitis) all others Outcome clinical signs • exclusively symptoms, quality of ... Presentation2.2-Session 2- Schmitt .ppt [Compatibility](https://reader034.vdocuments.mx/reader034/viewer/2022051801/5ade29ff7f8b9ae1408e02fb/html5/thumbnails/43.jpg)
Three Item Severity Scale (TIS)
![Page 44: Presentation2.2-Session 2- Schmitt .ppt neurodermatitis) all others Outcome clinical signs • exclusively symptoms, quality of ... Presentation2.2-Session 2- Schmitt .ppt [Compatibility](https://reader034.vdocuments.mx/reader034/viewer/2022051801/5ade29ff7f8b9ae1408e02fb/html5/thumbnails/44.jpg)
Three Item Severity Scale (TIS)
![Page 45: Presentation2.2-Session 2- Schmitt .ppt neurodermatitis) all others Outcome clinical signs • exclusively symptoms, quality of ... Presentation2.2-Session 2- Schmitt .ppt [Compatibility](https://reader034.vdocuments.mx/reader034/viewer/2022051801/5ade29ff7f8b9ae1408e02fb/html5/thumbnails/45.jpg)
Three Item Severity Scale (TIS)
![Page 46: Presentation2.2-Session 2- Schmitt .ppt neurodermatitis) all others Outcome clinical signs • exclusively symptoms, quality of ... Presentation2.2-Session 2- Schmitt .ppt [Compatibility](https://reader034.vdocuments.mx/reader034/viewer/2022051801/5ade29ff7f8b9ae1408e02fb/html5/thumbnails/46.jpg)
Six Area Six Sign Atopic DermatitisScore (SASSAD)
![Page 47: Presentation2.2-Session 2- Schmitt .ppt neurodermatitis) all others Outcome clinical signs • exclusively symptoms, quality of ... Presentation2.2-Session 2- Schmitt .ppt [Compatibility](https://reader034.vdocuments.mx/reader034/viewer/2022051801/5ade29ff7f8b9ae1408e02fb/html5/thumbnails/47.jpg)
Six Area Six Sign Atopic Dermatitis Score (SASSAD)
![Page 48: Presentation2.2-Session 2- Schmitt .ppt neurodermatitis) all others Outcome clinical signs • exclusively symptoms, quality of ... Presentation2.2-Session 2- Schmitt .ppt [Compatibility](https://reader034.vdocuments.mx/reader034/viewer/2022051801/5ade29ff7f8b9ae1408e02fb/html5/thumbnails/48.jpg)
Six Area Six Sign Atopic Dermatitis Score (SASSAD)
![Page 49: Presentation2.2-Session 2- Schmitt .ppt neurodermatitis) all others Outcome clinical signs • exclusively symptoms, quality of ... Presentation2.2-Session 2- Schmitt .ppt [Compatibility](https://reader034.vdocuments.mx/reader034/viewer/2022051801/5ade29ff7f8b9ae1408e02fb/html5/thumbnails/49.jpg)
Six Area Six Sign Atopic Dermatitis Score (SASSAD)
![Page 50: Presentation2.2-Session 2- Schmitt .ppt neurodermatitis) all others Outcome clinical signs • exclusively symptoms, quality of ... Presentation2.2-Session 2- Schmitt .ppt [Compatibility](https://reader034.vdocuments.mx/reader034/viewer/2022051801/5ade29ff7f8b9ae1408e02fb/html5/thumbnails/50.jpg)
Correlation matrix of clinical signs scores
![Page 51: Presentation2.2-Session 2- Schmitt .ppt neurodermatitis) all others Outcome clinical signs • exclusively symptoms, quality of ... Presentation2.2-Session 2- Schmitt .ppt [Compatibility](https://reader034.vdocuments.mx/reader034/viewer/2022051801/5ade29ff7f8b9ae1408e02fb/html5/thumbnails/51.jpg)
Summary of psychometric properties ofmeasures for clinical signs of eczema
![Page 52: Presentation2.2-Session 2- Schmitt .ppt neurodermatitis) all others Outcome clinical signs • exclusively symptoms, quality of ... Presentation2.2-Session 2- Schmitt .ppt [Compatibility](https://reader034.vdocuments.mx/reader034/viewer/2022051801/5ade29ff7f8b9ae1408e02fb/html5/thumbnails/52.jpg)
Conclusions
![Page 53: Presentation2.2-Session 2- Schmitt .ppt neurodermatitis) all others Outcome clinical signs • exclusively symptoms, quality of ... Presentation2.2-Session 2- Schmitt .ppt [Compatibility](https://reader034.vdocuments.mx/reader034/viewer/2022051801/5ade29ff7f8b9ae1408e02fb/html5/thumbnails/53.jpg)
Summary of findings
- 15 instruments identified to assess clinical signs of AD
- 3 new instruments since 2007 review
- some important validation work done in past 5years
- POEM not recommended to measure signs of AD
- EASI and (possibly) objective SCORAD are close tobe recommended
- SCORAD should be reported as a profile
- TIS and SASSAD: Consensus on content validityrequired to determine recommendation
![Page 54: Presentation2.2-Session 2- Schmitt .ppt neurodermatitis) all others Outcome clinical signs • exclusively symptoms, quality of ... Presentation2.2-Session 2- Schmitt .ppt [Compatibility](https://reader034.vdocuments.mx/reader034/viewer/2022051801/5ade29ff7f8b9ae1408e02fb/html5/thumbnails/54.jpg)
Suggested recommendations andresearch needs (I)
![Page 55: Presentation2.2-Session 2- Schmitt .ppt neurodermatitis) all others Outcome clinical signs • exclusively symptoms, quality of ... Presentation2.2-Session 2- Schmitt .ppt [Compatibility](https://reader034.vdocuments.mx/reader034/viewer/2022051801/5ade29ff7f8b9ae1408e02fb/html5/thumbnails/55.jpg)
Suggested recommendations and research needs (II)
![Page 56: Presentation2.2-Session 2- Schmitt .ppt neurodermatitis) all others Outcome clinical signs • exclusively symptoms, quality of ... Presentation2.2-Session 2- Schmitt .ppt [Compatibility](https://reader034.vdocuments.mx/reader034/viewer/2022051801/5ade29ff7f8b9ae1408e02fb/html5/thumbnails/56.jpg)
Jochen Schmitt, Stefanie Deckert, Sinead Langan, AkeSvensson, Laura von Kobyletzki, Kim Thomas, Phyllis Spuls
HOME IIIHOME IIIMeasurement properties of outcome
measurements for atopic eczema signs
San Diego, April 6-7, 2013
![Page 57: Presentation2.2-Session 2- Schmitt .ppt neurodermatitis) all others Outcome clinical signs • exclusively symptoms, quality of ... Presentation2.2-Session 2- Schmitt .ppt [Compatibility](https://reader034.vdocuments.mx/reader034/viewer/2022051801/5ade29ff7f8b9ae1408e02fb/html5/thumbnails/57.jpg)
BACK-UP SLIDES
![Page 58: Presentation2.2-Session 2- Schmitt .ppt neurodermatitis) all others Outcome clinical signs • exclusively symptoms, quality of ... Presentation2.2-Session 2- Schmitt .ppt [Compatibility](https://reader034.vdocuments.mx/reader034/viewer/2022051801/5ade29ff7f8b9ae1408e02fb/html5/thumbnails/58.jpg)
Contentvalidity
The degree to which the content of an instrument is anadequate reflection of the construct to be measured.
Constructvalidity
The degree to which the scores of an instrument areconsistent with hypotheses based the assumption that theinstrument validly measures the construct to be measured
Internalconsistency
The degree of interrelatedness among the items
Definition of measurement properties
Reliability The extent to which scores for patients who have notchanged are the same for repeated measurement underseveral conditions
Responsive-ness
The ability of an instrument to detect change over time in theconstruct to be measured
Interpretability The degree to which one can assign qualitative meaning –that is, clinical or commonly understood connotations – to aninstrument’s quantitative scores or changes in scores
![Page 59: Presentation2.2-Session 2- Schmitt .ppt neurodermatitis) all others Outcome clinical signs • exclusively symptoms, quality of ... Presentation2.2-Session 2- Schmitt .ppt [Compatibility](https://reader034.vdocuments.mx/reader034/viewer/2022051801/5ade29ff7f8b9ae1408e02fb/html5/thumbnails/59.jpg)
Summary of scale domains and items(scale content)
![Page 60: Presentation2.2-Session 2- Schmitt .ppt neurodermatitis) all others Outcome clinical signs • exclusively symptoms, quality of ... Presentation2.2-Session 2- Schmitt .ppt [Compatibility](https://reader034.vdocuments.mx/reader034/viewer/2022051801/5ade29ff7f8b9ae1408e02fb/html5/thumbnails/60.jpg)
Eczema area and severity index (EASI)
![Page 61: Presentation2.2-Session 2- Schmitt .ppt neurodermatitis) all others Outcome clinical signs • exclusively symptoms, quality of ... Presentation2.2-Session 2- Schmitt .ppt [Compatibility](https://reader034.vdocuments.mx/reader034/viewer/2022051801/5ade29ff7f8b9ae1408e02fb/html5/thumbnails/61.jpg)
Severity Scoring of Atopic Dermatitis Index(SCORAD)